Growth Metrics

Quest Diagnostics (DGX) Capital Expenditures (2016 - 2026)

Quest Diagnostics' Capital Expenditures history spans 18 years, with the latest figure at $114.0 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures fell 2.56% to $114.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $524.0 million, a 19.63% increase, with the full-year FY2025 number at $527.0 million, up 24.0% from a year prior.
  • Capital Expenditures hit $114.0 million in Q1 2026 for Quest Diagnostics, down from $158.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for DGX hit a ceiling of $158.0 million in Q4 2025 and a floor of $63.0 million in Q1 2022.
  • Historically, Capital Expenditures has averaged $110.5 million across 5 years, with a median of $108.0 million in 2025.
  • The widest YoY moves for Capital Expenditures: up 101.59% in 2023, down 51.02% in 2023.
  • Tracing DGX's Capital Expenditures over 5 years: stood at $147.0 million in 2022, then tumbled by 51.02% to $72.0 million in 2023, then soared by 70.83% to $123.0 million in 2024, then rose by 28.46% to $158.0 million in 2025, then fell by 27.85% to $114.0 million in 2026.
  • Business Quant data shows Capital Expenditures for DGX at $114.0 million in Q1 2026, $158.0 million in Q4 2025, and $144.0 million in Q3 2025.